The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.

The U.S. Food and Drug Administration has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe ...

If the FeNO level is not raised, it is recommended that the patient be offered either a Long-Acting Muscarinic Antagonist (LAMA) or a Leukotriene Receptor Antagonist (LTRA) on top of a moderate-dose ...

The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but ...

In the 12 months after starting tezepelumab, patients with severe asthma had fewer exacerbations, a lower cumulative oral ...

The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for ...

With a fresh endorsement from the FDA, the last of five major drug approvals has fallen into place for GSK in 2025. | Tuesday ...

Exploration of key clinical trial data and real-world evidence on dupilumab in asthma and COPD presented at the ERS and CHEST ...

Depemokimab-ulaa (Exdensur) is approved for severe asthma with an eosinophilic phenotype, offering protection with just two ...

The parents of a 13-year-old girl who died after an asthma attack led to a cardiac arrest have said they fear "other families will lose children because asthma is too easily dismissed".Emily Albino, ...

Vermont has one of the highest rates of pediatric asthma in the country — one analysis found that in Vermont, 8.3% of people under the age of 17 have asthma, according to 2023-24 data from the U.S.

AQI levels in Delhi crossed 400, in the severe category, on Tuesday, with several monitoring stations in the 'severe plus' ...